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 Introduction
People who inject drugs (PWID) in Thailand are a key affected population with high levels 
of Human Immunodeficiency Virus (HIV) prevalence over the last two decades. Thailand’s 
longstanding national HIV sentinel surveillance has reported high HIV prevalence (26–51%) 
among PWID and Songkhla has historically had the highest provincial prevalence levels 
over time (Bureau of Epidemiology, 2010b).
Despite the high HIV prevalence among PWID in Songkhla, there is a lack of systematic 
data on key issues such as drug use patterns, HIV risk behaviors and access to interventions. 
The national sentinel surveillance only reports data on HIV prevalence and these data are 
collected exclusively from PWID in drug treatment facilities. No behavioral data are 
monitored as part of this surveillance system. Moreover, most published studies have 
focused on PWID in the capital city of Bangkok and Northern Thailand (Choopanya et al., 
2013; Kerr et al., 2010; Razak et al., 2003; van Griensvan et al., 2005; Vanichseni et al., 
2004; Vongchak et al., 2005; Wattana et al., 2007). The few published studies in Songkhla, 
and Southern Thailand more broadly, were conducted at methadone treatment clinics and 
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may not be representative of community-based PWID (Perngmark, Celentano, & Kawichai, 
2003; Perngmark, Vanichseni, & Celentano, 2008; Saelim, Geater, Chongsuvivatwong, 
Rodkla, & Bechtel, 1998).
To address gaps in the understanding of the HIV epidemic among PWID in Songkhla, the 
Thai Bureau of Epidemiology (BOE) and its provincial partners conducted an integrated bio-
behavioral survey (IBBS) in Songkhla in 2010 with funding from the Global Fund and 
technical assistance from the Thailand Ministry of Public Health – U.S. Centers for Disease 
Control and Prevention Collaboration (TUC). The major objective of the survey was to 
describe the characteristics of community-based PWID in Songkhla to help inform the 
development of evidence-based interventions and a more robust surveillance system.
 Methods
 Setting
This cross-sectional IBBS survey was commenced during March to October 2010 at a 
methadone treatment clinic in Jana hospital located in Jana district of Songkhla province.
 Survey sampling
This survey used respondent-driven sampling (RDS), a sampling methodology 
recommended to sample hard-to-reach populations such as PWID (Johnston, Sabin, & 
Prybylski, 2010).
Survey staff selected an initial group of participants (‘seeds’) who in turn recruited their 
peers into the survey, continuing in multiple ‘waves’ of recruitment. Seeds were people who 
injected drugs in the past six months and were determined to have large diverse social 
networks. Seeds were diversely selected based on sex, age, type of drugs injected and 
methadone treatment status. A total of five seeds were selected by survey staff. Seeds 
provided voluntary informed consent, and provided with three referral coupons to recruit 
their peers.
The study sample size was based on feasibility of recruitment rather than precision of the 
prevalence estimate. We aimed to recruit at least 200 PWID to allow for estimation of HIV 
prevalence with an assumed prevalence of 24%. This allowed for a precision of ± 8.5%, with 
alpha = 0.05 and power (1 − β) = 0.80 using nQUERY 5.0 software (Statistic Solution, 
2002). A design effect of 2.0 was assumed.
 Inclusion criteria
Eligible PWID were aged ≥18 years, reported injecting illicit drugs in the last six months 
and were living or working in Songkhla province. They were also agreeable and able to 
provide informed consent, and had a valid referral coupon. Potential participants were 
screened by asking them to show injection marks. If no injection marks were observed, they 
would be asked to describe and/or demonstrate how they prepare and inject drugs. PWID 
who were intoxicated at the time of the survey were excluded from the survey.
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Survey staff from the Songkhla Provincial Health Office, Jana hospital and the Ozone drop-
in center were trained on RDS survey procedures, and with the assistance of a PWID peer, 
screened individuals arriving with a valid coupon to participate in the survey. Eligible and 
consenting participants completed a standardized behavioral questionnaire, using a self-
administered hand-held computer (HP iPaq hx2790b Pocket PC, Hewlett-Packard, Palo 
Alto, CA, USA.) or via face-to-face interview with a trained staff, where the interviewer 
directly inputted responses into the hand-held computer.
Survey staff provided HIV and STI pre-test counseling to all participants and collected blood 
samples (5 ml) for HIV testing. The samples were delivered to hospital laboratory to 
perform HIV testing following Thai national HIV diagnostic testing guidelines using three-
test algorithm. Samples were tested with the Determine HIV 1/2 (Abbott Japan Ltd, Tokyo, 
Japan) rapid test, and samples testing non-reactive were reported negative. Samples with 
reactive results were subjected to both second and third tests using the Serodia HIV 1/2 
(Fujirebio Inc., Tokyo, Japan) test and SD Bioline 3.0 (Standard Diagnostics Inc., Kyonggi-
do, South Korea) tests. Samples were considered HIV-positive if all three tests were reactive. 
Urine samples were also collected for sexually transmitted infections (STIs). Chlamydia 
trachomatis [CT] and Neisseria gonorrhoeae [NG] testing was conducted using the COBAS 
Amplicor CT/NG molecular test (Roche Molecular Systems, Branchburg, NJ, USA). Survey 
staff made appointments with participants to return to the survey site after two weeks to 
obtain both their HIV and STI test results. Post-test counseling was provided to participants 
who returned for their test results.
Finally, participants were given three coupons for recruiting their peers and a compensation 
of 200 Thai baht (6.7 USD) for their time for completing the survey and 50 baht (1.7 USD) 
for recruiting each peer. Those who returned for their HIV and STI test results received an 
additional compensation of 100 baht (3.3 USD). All participants with HIV or STI positive 
test results were referred to Jana hospital for follow-up care and treatment.
 Data management and analysis
Survey data from the interviews were transferred daily from the hand-held computers into a 
database program on the main survey computer created using MS Access 2003 and 2007 
software (Microsoft, Redmond, DC, USA). The RDS Analysis Tool (RDSAT) software 
version 6.0 (Cornell University, Ithaca, NY, USA) was used to generate adjusted proportion 
estimates weighted by degree (i.e. network size). Characteristic estimates that could not be 
generated by RDSAT were reported by proportion and 95% confidence interval was 
calculated using Binomial distribution.
 Ethical considerations
The survey protocol was approved as a non-research public health surveillance activity by 
the Ethical Review Committee, Thailand Ministry of Public Health, and the Institutional 
Review Board ofthe Centers for Disease Control and Prevention, Atlanta, USA.
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Characteristics of participants are shown in Table 1. Of the 202 participants, all but three 
were men, about half (53%) were 25 to 35 years of age, almost half of participants were 
unmarried and half had completed only primary school. Most (91%) were currently working 
and about three-quarters (76%) had a monthly income >5000 Thai baht (approximately 160 
USD).
 Injection and sexual behaviors
In the past one month, the majority of participants injected heroin (90%), followed by 
methamphetamine (22%) and mid-azolam (2%). One-third (37%) injected multiple drugs 
and most (87%) had been injecting for more than two years. The median frequency of 
injection in the past one month was ten times and 14% had experienced a drug overdose. 
Seven percent of participants reported using needles that had been used by others during 
their last injection. Among those reporting having had sexual intercourse in the past three 
months, only about one-quarter (27%) reported using a condom during their last sex act.
 HIV/STI prevalence and access to services
HIV prevalence was high (22%), with low CT (1%) and NG (0.6%) prevalence (Table 1). 
More than three-quarters of participants (78%) had been HIV tested in their lifetime and 
72% reported being tested for HIV in the past 12 months with their test results received. 
Most (83%) knew a place for HIV testing. Nearly half (42%) were currently on methadone 
treatment.
In the past 12 months, few participants received new needles (10%) and condoms (11%) 
from drop-in centers and/or peer outreach workers (Table 1). In the past month, pharmacies 
(65%) were the most popular place to obtain new needles, and about 1% received from drop-
in centers and/or peer outreach.
 Discussion
To our knowledge, this community-based survey is the first to use the probability-based 
RDS methodology to obtain a representative sample of PWID in Southern Thailand.
Among the overall survey sample we found that HIV prevalence was high (22%), injecting 
and sexual risk behaviors were common and access to HIV prevention programs was 
limited. Risk behaviors included needle-sharing, injection of multiple drugs and low condom 
use. Despite the reported lack of consistent condom use, STI prevalence was low (1%), a 
finding that may be explained by the low levels of casual (4%) and commercial (1%) sexual 
partnerships among participants and fairly high rates of recent HIV testing and counseling 
(72%). Drug overdose experience was also not uncommon (14%) which is an indicator of 
unsafe drug injection practices. In Bangkok, Thailand, a report of history of drug overdose 
was found to be associated with a history of incarceration and poly-drug use among a 
community-recruited PWID (Milloy et al., 2010), and drug overdose was the main cause of 
death among PWID participating in a cohort study (Choopanya et al., 2013). Nevertheless, it 
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is encouraging that the use of new needles at last injection is relatively high (92%) and that 
PWID are obtaining new needles from routinely available outlets such as pharmacies and 
private clinics and continued availability will remain important at these outlets. However, 
drop-in centers and peer outreach program appear under-utilized and there is a need to 
increase the coverage of more comprehensive community-based HIV prevention services 
and including information on drug overdose prevention and first aid for hard-to-reach 
PWID. However, it should be noted that these community-based programs were just initiated 
in 2009, only about one year before this survey was conducted.
In addition, we found that almost one-third of participants reported injecting multiple drugs 
including heroin, methamphetamine and midazolam. Even higher levels of multiple drug use 
have been reported in other areas of Thailand (Wattana et al., 2007). While heroin was still 
the major drug of choice (90%), injection of methamphetamine (22%) appears to be 
emerging among Songkhla PWID, compared to the earlier study among PWID in five 
southern provinces in the last decade that found that 91% injected only heroin (Perngmark et 
al., 2003). A shift from heroin to methamphetamine injection has also been observed in 
other areas of Thailand and Southeast Asia (Martin et al., 2010; van Griensvan et al., 2005; 
Vongchak et al., 2005). In 2010, a series of RDS-based IBBS surveys found high levels of 
methamphetamine injection in the last six months in both Chiang Mai (57%) and Bangkok 
(44%) that was much higher than we report in Songkhla. Injection of other drugs including 
midazolam (35%) and methadone (13%) had also become common among Bangkok PWID 
(Bureau of Epidemiology, 2010a). A similar trend was found in the recent Bangkok 
Tenofovir Study reported the predominant drugs injected in past 12 weeks were heroin 
(22%), methamphetamine (33%) and midazolam (23%) (Choopanya et al., 2013). It is 
thought that heroin use has decreased over time since the “war on drugs” campaign in 2003 
because of its increased price and due to the greater availability and lower price of other 
drugs (van Griensvan et al., 2005; Vongchak et al., 2005). Reported midazolam injection 
prevalence has been consistently higher in Bangkok than in others areas of Thailand, 
including Songkhla, as this is where midazolam distribution is focused and it is a cheap and 
easily accessible substitute for heroin (Kerr et al., 2010; Prybylski et al., 2015).
Our survey had a number of limitations. First, the findings were based on self-reported 
responses. Data may possibly subject to socially desirability bias especially when 
participants chose to complete a questionnaire through face-to-face interview with a survey 
staff. Nevertheless, the use of experienced and well trained staff conducting the interview, 
the use of a hand-held computer for participants to complete the questionnaire, and the 
promise to keep their confidentiality may have helped to reduce this bias. Second, it is 
possible that non-PWID participated because of the financial compensation available to the 
participants. To reduce the possibility of having non-PWID to participate, we trained a 
PWID peer to help the survey staff with systematic screening. Third, RDS survey data 
should be analyzed using RDSAT or similar software to adjust proportion estimates based on 
participants’ network size, however the small cell size for certain response categories meant 
that adjusted proportions could not be calculated in which case crude (i.e. unadjusted) 
proportions were reported instead.
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In conclusion, the Thai MOPH and partners were able to successfully implement RDS in 
Songkhla as a form of integrated bio-behavioral surveillance to more effectively monitor the 
HIV epidemic and the programmatic response in Songkhla and elsewhere. This survey was 
effective at recruiting PWID who were not currently in drug treatment, and provided 
information about this sub-group which had not been previously available in Songkhla or 
Southern Thailand more generally. Given the increasing trend of poly-drug injecting use 
documented among both in- and out-of-treatment PWID, it is recommended a 
comprehensive and integrated combination intervention approach for both HIV services (i.e., 
prevention and linkages to care and treatment) and drug treatment is adopted (Prybylski et 
al., 2015).
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Table 1




Male 199 99.6 98.8–100.0
Age group
 <25 years 13 7.5 3.1–12.1
 25–35 years 107 52.5 44.7–63.0
 >35 years 82 40.0 30.6–47.5
Marital status
 Single 95 46.7 37.8–55.8
 Married or living together 89 46.2 36.9–54.8
 Married but living separately, divorced or widowed 18 7.1 3.7–11.4
Education
 ≤Primary school (6 years of education) 100 47.6 38.0–57.0
 >Secondary school 102 52.4 43.3–62.0
Currently employed 181 90.5 85.6–95.1
Monthly income
 No income 24 10.6 6.0–15.4
 ≤5000 baht (~160 USD) 34 13.1 9.0–18.6
 >5000 baht 144 76.3 69.3–82.8
Injection behaviors
Type of drugs injected in past 1 month (multiple responses)
 Heroin 176 89.7 84.6–93.7
 Methamphetamine 49 21.8 15.5–30.4
 Midazolam 3 2.3 0.0–8.2
Multiple drug use in past 1 month (N = 177)
 Multiple drugs 68 36.5 28.4–47.2
 Single drug 109 63.5 52.8–71.6
Number of times of injected drugs in past 1 month (N = 177)
 1–10 times (median = 10) 97 49.1 41.3–57.8
 >10 times 80 46.9 36.6–56.5
Time since first started injecting
 ≤2 years 27 13.4a 9.0–18.8a
 >2–5 years 73 36.1a 29.5–43.2a
 >5 years 102 50.5a 43.4–57.6a
Used new needle at last injection 183 92.5 89.3–95.5
Used needle having been used by others at last injection 15 6.8 3.8–10.1
Overdose experience 27 13.9 9.5–19.0
Sexual behaviors
Had sexual intercourse in past 3 months 133 68.6 62.9–74.6
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Characteristics n RDSAT-adjusted
% 95% CI
Type of sexual partners among those having sex in past 3 months (multiple responses) (N = 133)
 Steady partner 121 64.2 57.6–70.6
 Casual partner 10 4.1 1.7–7.2
 Sex worker 5 0.9 0.4–2.6
Used condom at last sex with any partner in past 3 months 55 26.6 21.4–33.4
Currently in methadone treatment 104 42.2 33.1–52.4
Ever tested for HIV 164 78.1 71.3–85.1
Tested for HIV in past 12 months and knew the result 154 71.5 64.4–79.3
Knew the place for HIV testing 174 83.1 76.0–89.7
Places to get new needles in past 1 month (multiple responses)
 Department stores 24 13.7 8.3–20.0
 Places selling drugs 27 16.9 10.0–24.0
 Clinics 84 44.3 35.5–52.8
 Pharmacies 124 65.1 56.7–73.0
 Friends 7 2.8 0.6–5.7
 Drop-in centers or peer outreach workers 6 1.2 0.0–3.9
Have been to drop-in centers 38 19.2 12.2–30.2
Have met with peer outreach workers 32 12.9 6.8–23.7
Received new needles from drop-in centers/peer outreach workers in past 12 months 27 9.9 5.3–17.6
Received condoms from drop-in centers/peer outreach workers in past 12 months 30 10.6 5.8–18.2
HIV/STI prevalence
HIV positive 53 21.9 16.4–28.2
Chlamydia trachomatis (CT) positive 3 1.0 0.6–3.0
Neisseria gonorrhea (NG) positive 1 0.6 0.5–1.7
a
Crude percent and confidence interval as RDSAT could not generate results.
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